Disease by etiologic mechanism
MONDO:7770008A grouping class for human diseases classified by their etiologic mechanism, encompassing primarily intrinsic (genetic, genomic), primarily extrinsic (e.g., infections, toxins, radiation), and complex multifactorial (e.g. nutritional) causes.
56742 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 11731 trials in this tab.
-
Can a shorter radiation course spare the rectum in rectal cancer?
⭐️ CURE ⭐️ OngoingThis phase 3 trial tests two different ways of using radiation before chemotherapy in people with stage III rectal cancer. One group gets a short course of radiation, the other gets standard chemoradiation, both followed by chemotherapy. The goal is to see if either approach can …
Phase: PHASE3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 04:00 UTC
-
Could a Half-Matched donor cure a rare immune disease?
⭐️ CURE ⭐️ OngoingThis early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…
Phase: EARLY_PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 04:00 UTC
-
Can a single injection save sight in a rare retinal disease?
⭐️ CURE ⭐️ OngoingThis early-stage trial is testing whether a gene therapy called NGGT001, injected under the retina, is safe and tolerable for people with Bietti's crystalline dystrophy, a rare inherited condition that causes progressive vision loss. The study enrolls about 11 adults with a confi…
Phase: EARLY_PHASE1 • Sponsor: Xiamen Ophthalmology Center Affiliated to Xiamen University • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 04:00 UTC
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis early-stage trial is testing whether immune cells from a donor, specially trained to attack HIV, can safely reduce the hidden HIV reservoir in people who have had a bone marrow transplant. Participants are adults with HIV who are on antiretroviral therapy and have already re…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can a gene therapy restore natural hearing after cochlear implants?
⭐️ CURE ⭐️ OngoingThis trial tests an experimental gene therapy called EA0010 in children aged 1 to 17 with hearing loss caused by mutations in the OTOF gene, who already have cochlear implants. The therapy is injected into one ear and aims to deliver a working copy of the OTOF gene to inner ear c…
Phase: NA • Sponsor: Shanghai EmayGene Technology Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a single injection restore sight in a rare genetic eye disease?
⭐️ CURE ⭐️ OngoingThis trial tests an experimental gene therapy called NGGT001 for people with Bietti Crystalline Dystrophy, a rare inherited condition that causes progressive vision loss. The therapy is delivered as a single injection under the retina, aiming to replace a faulty gene with a worki…
Phase: PHASE1, PHASE2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a One-Time gene fix cure wilson disease?
⭐️ CURE ⭐️ OngoingThis trial tests an experimental gene therapy called MWAV201 in adults with Wilson disease, a genetic condition that causes copper to build up in the body. The treatment uses a harmless virus to deliver a corrected gene, potentially restoring the body's ability to remove copper. …
Phase: NA • Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a new TB vaccine protect children with HIV?
⭐️ VACCINE ⭐️ TerminatedThis trial is testing two tuberculosis (TB) vaccines—VPM1002 and a repeat BCG vaccination—in pre-adolescents aged 8-14 who were vaccinated at birth. The goal is to see if these vaccines are safe and trigger a strong immune response in children both with and without HIV, and in th…
Phase: PHASE1, PHASE2 • Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 18, 2026 04:00 UTC
-
Can the HPV vaccine protect those with a weak immune system?
⭐️ VACCINE ⭐️ OngoingThis study tests whether the HPV vaccine Gardasil 9 can trigger an immune response in people with idiopathic CD4 T cell lymphocytopenia (ICL), a rare condition that weakens the immune system. About 54 adults with ICL and some healthy volunteers will receive three doses of the vac…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 18, 2026 04:00 UTC
-
New west nile vaccine enters first human tests
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New tetanus vaccine enters first human safety tests
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new tetanus vaccine in 80 adults aged 18 and older. The study is randomized and double-blind, meaning neither participants nor doctors know who gets the new vaccine versus an existing one. The main goal is to check for side effects within the f…
Phase: PHASE1 • Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New eye injection aims to halt vision loss in dry AMD
Disease control OngoingThis early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision…
Phase: PHASE1, PHASE2 • Sponsor: Perceive Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Brain cancer breakthrough? new combo aims to shrink tumors in Hard-to-Treat glioblastoma
Disease control OngoingThis study tests whether adding a second chemotherapy drug, lomustine, to the standard treatment (temozolomide plus radiation) helps people with a specific type of glioblastoma live longer. The trial includes 265 adults with newly diagnosed tumors that have a methylated MGMT gene…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control TerminatedThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Could a common thyroid pill slow brain tumor growth?
Disease control TerminatedThis study tests methimazole, a drug normally used for thyroid problems, in people with progressive glioblastoma (a fast-growing brain tumor). Researchers want to see if it can help control the disease and how safe it is. About 19 adults will receive different doses to find the b…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Prostate cancer trial aims to tailor therapy based on genetic risk
Disease control OngoingThis phase 3 trial tests whether treatment for high-risk prostate cancer can be personalized based on a patient's genetic risk score. For those with a low genetic risk, a shorter course of hormone therapy plus radiation may be as effective as the standard 24-month treatment, with…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Promising combo targets genetic weakness in prostate cancer
Disease control OngoingThis Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New booster vaccine trial aims to shield japanese teens from three serious diseases
Disease control OngoingThis study tests a single booster dose of a combined vaccine against diphtheria, tetanus, and whooping cough (dTpa) in 85 healthy Japanese adolescents aged 11 to 13. Researchers will check if the shot triggers a strong immune response and monitor for side effects one month after …
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Blood test could guide chemo for throat cancer patients
Disease control OngoingThis study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Which lens implant method stays put better? a Head-to-Head test
Disease control OngoingThis study looks at whether the way a toric intraocular lens is implanted during cataract surgery affects how well it stays in place. Toric lenses correct astigmatism, but if they rotate after surgery, vision can blur. The trial compares two techniques: one using a gel-like subst…
Phase: NA • Sponsor: Ain Shams University • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a new stomach surgery tame acid reflux without hiding cancer risks?
Disease control OngoingThis trial tests whether a newer surgical technique, which combines sleeve gastrectomy with a rerouting of the digestive tract, can control acid reflux as well as the standard gastric bypass in adults with obesity. The new approach aims to keep the entire digestive tract visible …
Phase: NA • Sponsor: Victor Dib Institute • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can higher doses of TB drugs cut treatment time?
Disease control TerminatedThis phase II trial is investigating whether higher doses of two tuberculosis (TB) drugs, rifampicin and pyrazinamide, can safely shorten treatment for people with mild to moderate pulmonary TB. The study compares drug levels and safety of this high-dose regimen against the stand…
Phase: PHASE2 • Sponsor: University Hospital, Linkoeping • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for lung scarring: buloxibutid trial underway
Disease control OngoingThis Phase 2 trial tests an oral drug called buloxibutid in 378 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Over 52 weeks, researchers compare two doses of buloxibutid against a placebo to see if it can slow lung function decline. The study is double…
Phase: PHASE2 • Sponsor: Vicore Pharma AB • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug tarlatatamab shows promise in lung cancer trial
Disease control OngoingThis phase 2 trial is testing tarlatamab, an experimental drug given by IV, in 252 adults with small cell lung cancer that has worsened after platinum-based chemotherapy. The main goal is to see if the drug can shrink tumors (partial or complete response). Researchers will also m…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New weekly shot could help shed pounds in major obesity trial
Disease control OngoingThis large phase 3 trial is testing a new once-weekly injection called MET097 for weight loss in 3501 adults with obesity or overweight (but without diabetes). Participants will receive either the drug or a placebo for up to 84 weeks. The main goal is to see how much weight peopl…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can targeted radiation boost the power of immunotherapy against melanoma?
Disease control OngoingThis trial is investigating whether adding a short course of targeted radiation to a standard immunotherapy combination (ipilimumab and nivolumab) can improve outcomes for people with metastatic melanoma. Participants will receive the two immunotherapy drugs, and some will also r…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a Two-Drug combo outsmart advanced liver cancer?
Disease control OngoingThis early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Immunotherapy drug avelumab takes on rare thymus cancers
Disease control OngoingThis phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New cocktail targets Hard-to-Treat myeloma
Disease control OngoingThis early-stage trial is testing the safety of adding venetoclax to standard multiple myeloma treatments for people whose cancer cells have a specific genetic change called t(11;14). The study will enroll 100 participants and try different drug combinations to find the best dose…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Heated chemo during surgery: a new hope for ovarian cancer?
Disease control OngoingThis early-phase trial is testing whether giving heated chemotherapy directly into the abdomen during surgery is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive standard chemotherapy before surgery, and then either heated che…
Phase: EARLY_PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a targeted antibody take on glioblastoma?
Disease control OngoingThis phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants …
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for tough lymphoma: experimental drug CHO-H01 enters human trials
Disease control OngoingThis study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…
Phase: PHASE1, PHASE2 • Sponsor: Cho Pharma Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug shows promise for advanced skin cancer in early trial
Disease control OngoingThis study tests a new drug called INCB099280 in 63 adults with advanced squamous cell skin cancer that cannot be removed by surgery or radiation. The main goals are to see if the drug shrinks tumors and to check its safety. Participants take the drug and are monitored for side e…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Donor artery patch may fix Kids' windpipes in risky new surgery
Disease control ENROLLING_BY_INVITATIONThis study tests whether a piece of donated aorta (the body's largest artery) can be used as a patch to repair severe windpipe or bronchial defects in children. The surgery is for kids who cannot have standard windpipe repair. Only 5 children will be enrolled, and the main goal i…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Cancer drug ruxolitinib keeps flowing to stable patients in rollover trial
Disease control OngoingThis study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New pill could tame stubborn ulcerative colitis
Disease control OngoingThis study tests an oral drug called TAK-279 (Zasocitinib) in 207 adults with moderate-to-severe ulcerative colitis. Participants take either the drug or a placebo for 12 weeks, then everyone gets the drug for up to a year. The goal is to see if TAK-279 reduces bowel inflammation…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug AU409 enters first human trial for tough liver cancers
Disease control TerminatedThis early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Could skipping chemo speed up bladder cancer surgery without harm?
Disease control OngoingThis phase 3 trial asks whether removing the bladder right away is as effective as giving chemotherapy first, for patients with muscle-invasive bladder cancer who have no visible tumor left after a thorough biopsy. About 236 adults will be randomly assigned to either surgery alon…
Phase: PHASE3 • Sponsor: Regina Elena Cancer Institute • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Proton beam vs. X-Ray radiation: which is better for esophageal cancer?
Disease control OngoingThis study compares two radiation techniques for people with stage I to IVA esophageal cancer: proton beam therapy (which uses protons) and intensity modulated photon radiotherapy (which uses X-rays). The goal is to see which one works better at helping people live longer and cau…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can Lab-Made antibodies give HIV patients a break from daily pills?
Disease control OngoingThis study tests whether two lab-made antibodies, given as a single infusion, can help control HIV in adults who are starting standard antiretroviral therapy (ART). The trial will see if these antibodies reduce the hidden virus in blood cells and delay the virus from rebounding i…
Phase: PHASE2 • Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a new pill keep HER2-Positive breast cancer from coming back?
Disease control OngoingThis phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assi…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug combo aims to slow tough prostate cancer
Disease control OngoingThis Phase 3 trial tests whether adding talazoparib to enzalutamide can slow the spread of metastatic castration-resistant prostate cancer (mCRPC). About 1,054 men with this advanced cancer are taking either the drug combo or a placebo plus enzalutamide. The study tracks how long…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New cocktail of drugs shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of four drugs (gemcitabine, cisplatin, quemliclustat, and zimberelimab) as a first treatment for people with advanced biliary tract cancers, including bile duct cancer. The goal is to see if this mix can slow cancer growth and help people live longe…
Phase: PHASE2 • Sponsor: Nataliya Uboha • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo attack shows promise for Oligo-Metastatic lung cancer
Disease control OngoingThis phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cance…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Gene test guides prostate cancer therapy: more or less treatment?
Disease control OngoingThis phase III trial uses a genetic test (Decipher score) to personalize treatment for men with unfavorable intermediate-risk prostate cancer. For those with a high genetic risk, the study tests adding darolutamide to standard hormone therapy and radiation. For those with low gen…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a smart food program plus glucose tracking transform diabetes care?
Disease control OngoingThis study tests whether adding a continuous glucose monitor (CGM) and nutrition counseling to a food-as-medicine program helps adults with type 2 diabetes and food insecurity better manage their blood sugar. Sixty participants will be split into two groups: one gets the standard…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Experimental vaccine aims to stop lung cancer from coming back
Disease control TerminatedThis trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New obesity drug candidate cagrilintide gets closer look in early trial
Disease control OngoingThis early-stage study will compare two different versions of the drug cagrilintide in 50 adults with overweight or obesity. Participants will receive injections of either version for several weeks, and researchers will measure how the drug builds up in the body. The goal is to s…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo aims to stall advanced breast cancer
Disease control OngoingThis study tests whether adding the experimental drug capivasertib to standard hormone therapy and CDK4/6 inhibitors can delay cancer growth in people with advanced HR+/HER2- breast cancer that cannot be removed by surgery or has spread. About 895 adults whose cancer has not resp…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Which lens implant delivers sharper sight after cataract surgery?
Disease control OngoingThis trial compares two types of intraocular lenses implanted during cataract surgery: the Clareon PanOptix and the Tecnis Odyssey. About 266 adults with cataracts in both eyes will receive one lens type in each eye, and researchers will measure how well they see at various dista…
Phase: NA • Sponsor: Nvision Laser Eye Centers • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug combo aims to boost Radiation's punch against childhood brain tumors
Disease control OngoingThis study tests a new drug called AZD1390 given alongside radiation therapy for children with aggressive brain tumors (high-grade glioma, DIPG, or DMG). The drug blocks cancer cells from repairing damage caused by radiation, potentially making treatment more effective. About 54 …
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a quick zapping of bone spots prevent fractures? new trial aims to find out
Disease control OngoingThis phase 3 trial is testing whether adding radiation therapy to standard care can prevent bone complications like fractures or spinal cord compression in cancer patients with high-risk bone metastases that aren't causing symptoms yet. About 280 patients with multiple metastatic…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug combo aims to stop prostate cancer spread after surgery
Disease control OngoingThis phase III trial tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to nearby lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New biologic mirikizumab put to the test against standard therapies for IBD
Disease control ENROLLING_BY_INVITATIONThis study compares the real-world effectiveness of mirikizumab against standard biologic therapies for adults with ulcerative colitis or Crohn's disease. Researchers will track whether mirikizumab reduces the need for extra medical care, like emergency visits or treatment change…
Phase: PHASE4 • Sponsor: Specialty Networks Research. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New split-dose chemo aims to help elderly lymphoma patients
Disease control OngoingThis study tests a modified schedule of standard chemotherapy (R-CHOP) for people aged 75 and older with diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. Twenty-seven p…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo therapy aims to deepen remission in multiple myeloma
Disease control OngoingThis phase 3 trial tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will participate. The goal is to see if …
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New cocktail of cancer drugs shows promise in early lymphoma trial
Disease control OngoingThis early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. About …
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New stem cell approach aims to cure rare immune disease
Disease control OngoingThis study tests a high-dose stem cell transplant for people with chronic granulomatous disease (CGD), a condition that weakens the immune system. Participants receive donor stem cells along with drugs to prevent rejection and graft-versus-host disease. The goal is to improve tra…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted pill plus hormone therapy shows promise
Disease control OngoingThis phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug shows promise for tough brain cancers
Disease control OngoingThis phase 2 trial tests the drug erdafitinib in 30 adults with a specific type of brain tumor (IDH-wild type glioma) that has come back or is getting worse. The tumor must have a certain gene fusion (FGFR-TACC). Erdafitinib blocks a faulty protein that helps cancer cells grow. T…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control TerminatedThis study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Could removing extra lymph nodes during prostate surgery stop cancer from coming back?
Disease control OngoingThis trial asks whether removing lymph nodes during prostate cancer surgery lowers the chance of the cancer returning. Men with clear scans before surgery are randomly assigned to have lymph nodes removed or not. The study also tests other surgical tweaks, like how the incision i…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New antibody combo shows promise for Hard-to-Treat myeloma
Disease control OngoingThis early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, i…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo therapy aims to halt spreading prostate cancer
Disease control OngoingThis phase II trial tests whether adding the hormone-blocking drug relugolix to standard radiation therapy can slow cancer growth in men with prostate cancer that has spread to a few other spots in the body (oligometastatic). About 194 participants will receive either radiation a…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Light-Activated dye could save sight from severe eye infections
Disease control OngoingThis study tests whether a light-activated dye called rose Bengal, combined with antibiotics and steroids, can improve vision in people with severe bacterial eye infections. About 60 adults with corneal ulcers and vision loss will receive either the dye treatment or a sham proced…
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
One-Time gene shot could free gaucher patients from lifelong infusions
Disease control OngoingThis early-stage study tests a single intravenous dose of a gene therapy called LY3884961 in 15 adults with Gaucher disease type 1. The goal is to see if it is safe and can reduce or replace the need for ongoing enzyme replacement or substrate reduction therapy. Participants must…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Smart pillbox sends alerts to keep HIV treatment on track
Disease control OngoingThis trial tests a smart pillbox that sends text alerts when a person misses their HIV medication. The alerts go to the user, a support person, and a case manager to help them get back on track. The study involves African American men who have sex with men and have trouble sticki…
Phase: PHASE3 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug combo aims to outperform standard therapy for advanced breast cancer
Disease control OngoingThis Phase 3 trial is testing whether a new drug called giredestrant, combined with palbociclib, works better than the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive eit…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can an ancient herbal formula beat antibiotics for urinary infections?
Disease control OngoingThis phase 2 trial is testing whether a traditional Chinese medicine called Lishitonglin Formula can improve non-severe urinary tract infections and lower urinary tract symptoms in men with urethral stricture before they undergo surgery. Participants will take either the herbal f…
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New lupus drug afimetoran enters Mid-Stage trial
Disease control OngoingThis phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …
Phase: PHASE2 • Sponsor: Beeline Medicines Corporation • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Eye transplant showdown: which surgery saves sight best?
Disease control OngoingThis study compares two types of corneal transplant surgery (UT-DSAEK and DMEK) in 160 people with Fuchs dystrophy, a condition that clouds the cornea. It also tests whether a drug called rho-kinase inhibitor can reduce loss of important eye cells after surgery. The goal is to fi…
Phase: PHASE3 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Weekly shot shows promise for helping kids with dwarfism grow
Disease control ENROLLING_BY_INVITATIONThis study tests a weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who completed a previous TransCon CNP trial can join thi…
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Inhaled drug combo aims to boost lung cancer treatment before surgery
Disease control TerminatedThis study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Experimental cocktail targets Hard-to-Treat brain cancer
Disease control OngoingThis early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug combo aims to boost immune system against hard-to-treat urinary cancers
Disease control OngoingThis early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in 100 adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination can help the immune system fight cancer better…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug cocktail targets Hard-to-Treat colon cancer mutation
Disease control OngoingThis early-phase trial is testing whether adding a new targeted drug called adagrasib to two existing cancer drugs (cetuximab and irinotecan) is safe and tolerable for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. The study will enrol…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill shows promise against tough lung cancer mutation
Disease control OngoingThis study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already tried chemotherapy. The goal is to see if the drug shrinks tumors and how sa…
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can surgery boost control of spread prostate cancer?
Disease control OngoingThis study tests whether robot-assisted removal of the prostate, along with lymph node dissection, can help control cancer in men with oligometastatic hormone-sensitive prostate cancer—cancer that has spread to a few spots in the spine or pelvis. Participants have been on hormone…
Phase: NA • Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a blood pressure pill protect your liver from cancer?
Disease control OngoingThis phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis m…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Cancer drug targets genetic weakness in advanced tumors
Disease control OngoingThis phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Immunotherapy drug shows promise against deadly thyroid cancer
Disease control TerminatedThis study tests a drug called vudalimab in people with advanced anaplastic thyroid cancer or aggressive hurthle cell thyroid cancer that has spread. The drug helps the immune system attack cancer cells and may slow tumor growth. About 54 participants will receive the treatment t…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug durvalumab to the usual chemotherapy and radiation treatment can help people with locally advanced anal cancer stay cancer-free longer. The study includes about 180 adults with stage IIB–IIIC anal cancer. Partici…
Phase: PHASE2 • Sponsor: Goethe University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene fix trial aims to tame rare immune disease
Disease control ENROLLING_BY_INVITATIONThis study tests a gene therapy for people with X-linked chronic granulomatous disease (X-CGD), a genetic condition that weakens the immune system and leads to severe infections. Researchers take the patient's own stem cells, add a working copy of the faulty gene, and return the …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New targeted drug aims to outperform chemo in tough lung cancers
Disease control OngoingThis Phase 3 trial compares a new drug called MK-2870 (sacituzumab tirumotecan) with standard chemotherapy (docetaxel or pemetrexed) in 556 adults with advanced non-squamous non-small cell lung cancer that has specific genetic changes (EGFR mutations or others) and has worsened a…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can immune cells plus a checkpoint drug outsmart lymphoma?
Disease control OngoingThis early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, whic…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a blood gel with antibiotics speed wisdom tooth healing?
Disease control OngoingThis trial tests whether adding an antibiotic to a blood-derived gel (platelet-rich fibrin) placed in the socket after wisdom tooth removal improves recovery. It compares the antibiotic-enriched gel to a standard gel in the same person, measuring swelling, pain, and infection ris…
Phase: NA • Sponsor: Amerigo Giudice • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to slow kidney failure in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests sefaxersen, a drug that targets a part of the immune system, in 428 people with IgA nephropathy at high risk of kidney decline. Participants receive either sefaxersen or a placebo as a shot under the skin. The main goal is to see if the drug reduces prote…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New UV laser could make LASIK safer and more precise
Disease control OngoingThis study tests a new ultraviolet femtosecond laser for creating corneal flaps during LASIK surgery to correct refractive errors. About 128 participants in Australia will receive LASIK using either the new UV laser or an existing infrared laser. The main goal is to check how saf…
Phase: NA • Sponsor: Alcon Research • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New daily pill could help millions shed pounds and improve health
Disease control OngoingThis study tests a new daily pill, orforglipron, to help adults with obesity or overweight who also have weight-related conditions like high blood pressure or sleep apnea lose weight. About 3,100 participants will take either the pill or a placebo for 72 weeks, with some continui…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to stop liver Cancer's return in High-Risk patients
Disease control OngoingThis study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New stem cell therapy aims to tame transplant complications
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Lung cancer drug adagrasib: which dose works best?
Disease control OngoingThis phase 2 study compares two dosing schedules of the targeted drug adagrasib (Krazati) in 200 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried chemotherapy and immunotherapy. The goal is to see if a lower d…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot could tame high cholesterol without statins
Disease control OngoingThis Phase 3 trial tests a new injectable drug called IBI306 in 198 Chinese adults with non-familial high cholesterol and mixed high lipids. Participants receive either IBI306 or a placebo every 2 or 4 weeks for 12 weeks. The main goal is to see how much the drug lowers LDL (bad)…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Cholesterol drug paired with immunotherapy shows promise for tough kidney cancer
Disease control OngoingThis phase 2 trial tests whether adding evolocumab (a cholesterol-lowering drug) to nivolumab (an immunotherapy) can help control metastatic kidney cancer that has not responded to prior treatments. Only 10 participants are enrolled, and the main goal is to check safety and side …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A gentler path after surgery for HPV throat cancer?
Disease control OngoingThis phase 2 trial is testing whether people with HPV-related throat cancer can safely receive lower doses of radiation and chemotherapy after surgery, compared with the standard full-intensity approach. The goal is to see if this lighter treatment helps preserve swallowing funct…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control OngoingThis study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a newer immunotherapy drug keep melanoma from coming back?
Disease control OngoingThis phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New epilepsy drug tested for Long-Term safety in kids
Disease control OngoingThis study looks at the long-term safety of the drug brivaracetam in children and teenagers with childhood absence epilepsy or juvenile absence epilepsy. About 120 participants who have already taken the drug in earlier studies will continue treatment and be monitored for side ef…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hearing implant trial aims to help kids hear better
Disease control OngoingThis study tests the Sentio bone-anchored hearing system in 50 children aged 3 to 11 with hearing loss or single-sided deafness. The device is already approved for older kids and adults. Researchers want to see if it safely improves hearing compared to no aid. The trial is happen…
Phase: NA • Sponsor: Oticon Medical • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Nudge study aims to help HIV smokers quit
Disease control ENROLLING_BY_INVITATIONThis study looks at whether sending reminders (nudges) to doctors, patients, or both can increase the number of people with HIV who smoke getting help to quit. About 500 patients and their doctors are involved. The goal is to see if these nudges lead to more referrals and partici…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can good bacteria beat bladder infections? new study investigates
Disease control OngoingThis study tests whether taking a probiotic (a 'good' bacteria) can help women who get frequent urinary tract infections (UTIs). About 90 women with a history of repeat UTIs will take either a probiotic or a placebo (a dummy pill) for 6 months. The goal is to see if the probiotic…
Phase: NA • Sponsor: ProbiSearch SL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New Three-Drug cocktail targets Hard-to-Treat bladder cancer
Disease control OngoingThis phase 2 trial tests a combination of three drugs—pemetrexed, etrumadenant, and zimberelimab—in 10 people with advanced bladder cancer that has a specific genetic change (MTAP deficiency) and has already been treated with immunotherapy. The goal is to see if the combo is safe…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
One pill to beat worms? new drug emodepside takes on mebendazole
Disease control OngoingThis phase 3 trial tests whether a single dose of emodepside can cure soil-transmitted worm infections (like whipworm, hookworm, and roundworm) better than the standard 3-day course of mebendazole. About 315 adolescents and adults with confirmed infections will receive either emo…
Phase: PHASE3 • Sponsor: Swiss Tropical & Public Health Institute • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New vaccine-antibody combo takes on pancreatic cancer
Disease control OngoingThis study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug cocktail shows promise for rare muscle disease
Disease control OngoingThis phase 2 study tests a combination of two nucleoside drugs, doxecitine and doxribtimine, in 47 people with thymidine kinase 2 (TK2) deficiency, a rare genetic disorder that weakens muscles. Participants already receiving nucleoside therapy continue treatment to see if the dru…
Phase: PHASE2 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can leaving some decay save the tooth? a trial tests two gentle approaches
Disease control OngoingThis study compares two conservative methods for treating deep tooth decay that reaches close to the nerve. In one approach, dentists leave softer decayed tissue near the nerve; in the other, they remove more until firmer tissue remains. About 100 patients with deep decay in perm…
Phase: NA • Sponsor: King Abdullah University Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with rare cancers: alectinib trial launches
Disease control OngoingThis study tests the drug alectinib in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to other treatments or have no standard therapy. The goal is to see if alectinib is safe and can shrink or control these tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can cord blood t cells be trained to stop viral infections after transplant?
Disease control OngoingThis trial is testing whether specially grown T cells from cord blood can help prevent or treat infections caused by common viruses (CMV, EBV, BKV, and adenovirus) in people who have had a cord blood transplant. The study aims to find the safest and most effective dose of these v…
Phase: PHASE1, PHASE2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Special blood storage could cut transfusions for cancer patients
Disease control OngoingThis study tests whether red blood cells stored with less oxygen (hypoxic RBCs) are safer and more effective than standard transfusions for people with blood cancers who need regular blood. About 24 adults with transfusion-dependent blood cancers will receive both types of blood …
Phase: NA • Sponsor: Hemanext • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Umbilical cord stem cells aim to slow muscle loss in duchenne boys
Disease control OngoingThis study tests whether stem cells from donated umbilical cords can help boys with Duchenne muscular dystrophy (DMD). The cells are given through a vein and are meant to reduce inflammation and improve muscle function. The trial includes boys aged 5 to 10 who can still walk and …
Phase: PHASE2 • Sponsor: MED Institute Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma? early trial of ABBV-291 begins
Disease control OngoingThis early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Poop pills may tame severe immunotherapy side effects in cancer patients
Disease control TerminatedThis study tests a treatment made from healthy donor stool (MTP-101-C) for cancer patients whose skin or gut side effects from immunotherapy don't get better with steroids. About 30 participants will take the oral capsules to see if the therapy is safe and can calm these side eff…
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Scientists reprogram immune cells to attack common cancer mutation
Disease control OngoingThis early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug keep Crohn's disease in check?
Disease control OngoingThis clinical trial is testing whether risankizumab, an experimental drug, can safely and effectively maintain remission in people with moderate to severe Crohn's disease who have already responded to initial treatment. Participants will receive either risankizumab or a placebo f…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat myeloma
Disease control OngoingThis early-stage study tests a new drug called etentamig combined with standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 320 adults will take part to find the safest dose and check for side effects. The goal is to cont…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New eye drug implant could reduce injections for wet AMD
Disease control OngoingThis study tests a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is given either as an eye injection or through a small implant placed in the eye that releases the drug over time. The trial involv…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill outsmart resistant prostate cancer?
Disease control OngoingThis trial is testing an experimental oral drug called ODM-208 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to find the highest safe dose and to assess t…
Phase: PHASE1, PHASE2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced kidney cancer: Triple-Drug combo shows promise
Disease control OngoingThis study tests if adding another drug (belzutifan or quavonlimab) to a standard two-drug treatment can help people with advanced clear cell kidney cancer live longer or stop their cancer from growing. About 1,650 adults who have not had prior treatment for advanced disease will…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a targeted drug boost chemo for osteosarcoma?
Disease control TerminatedThis trial is testing whether adding the targeted drug cabozantinib to standard chemotherapy (methotrexate, doxorubicin, and cisplatin) helps people with newly diagnosed osteosarcoma, a type of bone cancer. The study includes over 1,100 participants and aims to see if the combina…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can trained immune cells outsmart brain tumors?
Disease control OngoingThis Phase I trial tests whether infusing specially trained immune cells, called TAA-T, can safely target and attack high-risk brain tumors in children and adults. The cells are made from the patient's own blood and are designed to recognize multiple tumor-related proteins, poten…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Experimental drug GLM101 targets rare PMM2-CDG in pivotal trial
Disease control OngoingThis study tests a drug called GLM101 for people with PMM2-CDG, a rare inherited disease that affects movement and coordination. About 50 children and adults will receive weekly infusions of either GLM101 or a placebo for 24 weeks, followed by an open-label phase where everyone g…
Phase: PHASE2, PHASE3 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called tuvusertib, given alone or with another drug (niraparib), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo therapy aims to boost liver cancer surgery success
Disease control OngoingThis early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the com…
Phase: PHASE1 • Sponsor: Jiping Wang, MD, PhD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug tofersen under watch for ALS patients in china
Disease control OngoingThis study checks the long-term safety of tofersen (Qalsody) in 12 Chinese adults with a specific genetic form of ALS (SOD1-ALS). Participants receive 13 doses of the drug injected into the spine over about a year. The main goal is to track any side effects and how the drug moves…
Phase: PHASE4 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a laser beam save your tooth and ease pain better than traditional methods?
Disease control OngoingThis trial compares two ways to treat a severely decayed tooth that has caused irreversible pulpitis, a painful condition where the tooth's inner pulp is inflamed. One method uses a standard solution to control bleeding after removing damaged pulp, while the other uses a diode la…
Phase: NA • Sponsor: King Abdullah University Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Weekly shot may help short kids grow – new study underway
Disease control OngoingThis study tests a new growth hormone medicine called somapacitan, given once a week, in 47 children who are very short due to being born small for gestational age, or having Turner syndrome, Noonan syndrome, or idiopathic short stature. The main goal is to see if it is safe and …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for NF1 patients: drug shows promise against inoperable tumors
Disease control OngoingThis study tests a drug called selumetinib in adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink these tumors or slow their growth. Participants take the drug twice daily and are monitored …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for blood disorder patients: experimental drug bomedemstat enters final trial phase
Disease control OngoingThis study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia (a blood disorder causing too many platelets) who did not respond well to or couldn't tolerate the standard drug hydroxyurea. About 340 adults will be ra…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can continued therapy keep OCD symptoms at bay?
Disease control OngoingThis study offers open/aftercare treatment to adults with obsessive-compulsive disorder (OCD) who have completed an earlier study at Stanford's Rodriguez Lab. Participants receive evidence-based psychotherapy and/or pharmacotherapy from trained professionals. The goal is to see i…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Coffee grounds probiotic could reshape gut health and fight inflammation
Disease control OngoingThis pilot study tests whether a daily probiotic supplement containing L. acidophilus (strain TW01), originally isolated from fermented coffee grounds, can improve gut health, body composition, and markers of inflammation. Overweight or obese adults aged 18-60 will take either th…
Phase: EARLY_PHASE1 • Sponsor: University of Connecticut • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
Disease control TerminatedThis study tests whether giving the drug anakinra early can prevent severe cytokine release syndrome (CRS) in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) who are receiving CAR-T cell therapy. Participants receive anakinra at the first sign of fever,…
Phase: PHASE1, PHASE2 • Sponsor: Kevin McNerney • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a nutrient in eggs boost brainpower in starving kids?
Disease control OngoingThis study tests whether adding choline to a peanut-based therapeutic food improves cognitive development in 1,500 Malawian children aged 6-59 months with severe acute malnutrition. Half get standard food, half get food with extra choline. All also receive amoxicillin. The goal i…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can precision protons spare the bowel in prostate cancer?
Disease control OngoingThis trial tests whether proton therapy, a more precise form of radiation, causes fewer long-term bowel side effects than standard photon therapy in men with high-risk prostate cancer. Participants receive the same radiation dose and schedule, but one group gets protons and the o…
Phase: NA • Sponsor: University of Aarhus • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancer mutation in early trial
Disease control OngoingThis study tests an experimental oral drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific mutation in the KRAS gene (G12C). The trial aims to find the best dose and check if the drug is safe and can shrink tumors. About 315 adults whose ca…
Phase: PHASE1, PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
One-Day liver cancer treatment could cut hospital time in half
Disease control OngoingThis study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a simpler procedure save children's aching baby teeth?
Disease control OngoingThis trial tests whether a less invasive dental procedure called pulpotomy can successfully treat baby molars with a severe, painful tooth condition known as irreversible pulpitis. Instead of removing the entire nerve, pulpotomy removes only the top part and places a soothing med…
Phase: NA • Sponsor: Qatar University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new biologic boost standard brain cancer therapy?
Disease control OngoingThis trial is testing whether adding an experimental drug called XS005 to the standard chemotherapy regimen (Stupp) is safe and shows promise for people with glioblastoma, an aggressive brain tumor. The study involves 13 adults aged 18 to 70 who will receive XS005 infusions over …
Phase: PHASE1, PHASE2 • Sponsor: Dushu Lake Hospital Affiliated to Soochow University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase: PHASE2, PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of cushing syndrome
Disease control OngoingThis study looks at the long-term safety of relacorilant, a drug for people with Cushing syndrome. It includes 125 adults who previously completed a relacorilant study and may benefit from continued treatment. Researchers will track side effects over time to see if the drug is sa…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New study tracks Selumetinib's Real-World impact on kids with NF1 tumors
Disease control OngoingThis study follows about 80-100 Chinese children aged 3-16 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. All participants take the drug selumetinib (Koselugo) and are monitored for 24 months to see how well it works and what side ef…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail aims to tame Hard-to-Treat breast cancer
Disease control OngoingThis early-stage trial is testing a new drug called GDC-9545 (giredestrant), alone or combined with other medications, in people with advanced ER-positive breast cancer that has spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 18…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug shows promise in lung cancer with brain spread
Disease control OngoingThis study tests whether a newer targeted drug, entrectinib, works better than the current standard drug, crizotinib, for people with advanced lung cancer that has a specific genetic change (ROS1). About 220 participants will take one of the two pills daily. The study focuses on …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Eat less time, move more: new study tests Fat-Burning combo
Disease control OngoingThis study looks at whether eating only during a set window each day combined with short, intense exercise can help overweight adults lose fat and improve health markers like blood sugar and cholesterol. One hundred participants will follow this routine remotely for 12 months, wi…
Phase: NA • Sponsor: Norwegian University of Science and Technology • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can pressurized breathing boost mucus clearance in lung disease?
Disease control OngoingThis trial investigates whether delivering a mucus-thinning medication (NAC) with positive airway pressure improves its ability to clear mucus plugs in the lungs of people with asthma or COPD. Participants will receive NAC plus albuterol through either a standard nebulizer or a d…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail shows promise for rare HIV-Linked cancer
Disease control OngoingThis early-phase trial tested whether combining two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), is safe and tolerable for people with advanced or hard-to-treat Kaposi sarcoma. The study enrolled 62 adults, including those wit…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo therapy hopes to tackle rare skin cancer
Disease control TerminatedThis phase II trial tests whether combining a targeted antibody drug (mogamulizumab) with a procedure that treats white blood cells with light (extracorporeal photopheresis) can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advan…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Bladder cancer surgery: do stents help or hurt?
Disease control TerminatedThis study looks at whether using ureteral stents (small tubes) after bladder cancer surgery leads to more or fewer problems than not using them. About 190 adults having their bladder removed will be randomly assigned to get stents or not. The main goal is to see who ends up back…
Phase: PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New daily injection could cut bleeding episodes in hemophilia
Disease control OngoingThis study tests a medicine called concizumab for people with hemophilia A or B who do not have inhibitors. The goal is to see if a daily shot under the skin can prevent bleeding episodes safely. About 156 participants, aged 12 and older, will either start concizumab right away o…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for kids with NF1 brain tumors: targeted drug may beat chemo
Disease control OngoingThis study compares a targeted drug called selumetinib to standard chemotherapy (carboplatin/vincristine) in children aged 2 to 21 with neurofibromatosis type 1 (NF1) and low-grade glioma, a type of brain tumor. The goal is to see if selumetinib works as well or better at control…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can improve outcomes for people with locally advanced nasopharyngeal carcinoma, a type of head-and-neck cancer. Participants will receive either toripalimab or a…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for lung cancer patients: experimental drug aims to extend life after other treatments fail
Disease control OngoingThis study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare bone cancer? drug shows promise in early trial
Disease control OngoingThis phase 2 trial tested vismodegib, a pill that targets a specific growth pathway, in 45 people with advanced chondrosarcoma (a rare bone cancer). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had to have measurable disease and no m…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThis trial compares the drug ruxolitinib against the best available standard treatments for people with high-risk polycythemia vera (PV) or essential thrombocythemia (ET), two rare blood cancers that cause overproduction of blood cells and can lead to clots, bleeding, and severe …
Phase: PHASE2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to cut sickle cell pain crises in half
Disease control OngoingThis phase 3 study tests two doses of crizanlizumab against a placebo in 255 adolescents and adults with sickle cell disease who have frequent pain crises. The goal is to see if the drug can reduce the number of severe pain episodes that require a hospital or clinic visit. Partic…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New study tracks Maribavir's Real-World success against Post-Transplant CMV
Disease control OngoingThis study follows 75 adults who have had a stem cell or solid organ transplant and are being treated with maribavir for cytomegalovirus (CMV) infection. Researchers will track how well the drug clears the virus, how long treatment lasts, and any side effects. The goal is to see …
Sponsor: Takeda • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Ceramic hip resurfacing: a Metal-Free future for joint replacement?
Disease control OngoingThis study is testing a new type of hip resurfacing device made entirely of ceramic, designed for people with hip osteoarthritis, necrosis, or dysplasia. The goal is to see if it is as safe and effective as existing metal-on-metal devices, but without releasing metal ions into th…
Sponsor: Embody Orthopaedic Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental cocktail aims to outsmart resistant myeloma
Disease control OngoingThis early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radioactive drug takes on brain cancer in early trial
Disease control OngoingThis early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is …
Phase: PHASE1 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radioactive drug lutathera tested against Hard-to-Treat meningioma
Disease control OngoingThis Phase 2 trial tests whether the radioactive drug Lutathera can slow or stop the growth of progressive meningioma, a type of brain tumor. About 153 adults with grade 1-3 meningioma will be randomly assigned to receive Lutathera or standard treatments like bevacizumab or evero…
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a modified interferon rein in early myelofibrosis?
Disease control OngoingThis phase 3 trial is testing whether ropeginterferon alfa-2b, a biologic drug, can help control blood cell counts and symptoms in adults with early or low-risk primary myelofibrosis, a bone marrow disorder. Participants receive either the drug or a placebo every two weeks for up…
Phase: PHASE3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Laser or freezing: a gentler approach to prostate cancer?
Disease control ENROLLING_BY_INVITATIONThis pilot study is testing a device that uses ultrasound images to guide a laser or freezing probe directly into prostate tumors. The goal is to destroy only the cancerous tissue while sparing healthy areas. Thirty men with low- to intermediate-risk prostate cancer that hasn't s…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo aims to shrink metastatic kidney tumors
Disease control OngoingThis study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose an…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control OngoingThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could an arthritis drug help kids with duchenne MD? new trial aims to find out
Disease control OngoingThis study tests satralizumab, a drug that calms inflammation, in 30 children aged 8 to 17 with Duchenne muscular dystrophy. The goal is to see if it improves bone density and muscle function. Participants receive injections for several months while continuing standard steroid th…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Brain pacemaker tested for Musician's hand cramps
Disease control OngoingThis study tests deep brain stimulation (DBS) surgery for people with severe focal hand dystonia, including musician's dystonia, that hasn't improved with botulinum toxin. Five participants will have electrodes placed in brain areas that control movement, connected to a stimulato…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
App aims to keep HIV patients with addiction on track
Disease control OngoingThis study tests a mobile app called Connections for people living with HIV who also have substance use disorders. The app provides resources, weekly check-ins, discussion rooms, and private messaging with peer mentors and care teams. Researchers want to see if using the app help…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Dual-Action pill tame bone marrow tumors?
Disease control TerminatedThis phase 1 trial is testing an experimental pill called flonoltinib maleate in people with certain bone marrow tumors, including myelofibrosis, polycythemia vera, and essential thrombocythemia. The drug targets two proteins involved in abnormal blood cell growth. The study aims…
Phase: PHASE1 • Sponsor: Guizhou Bailing Group Pharmaceutical Co Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New balloon coated with drug aims to keep leg arteries open longer
Disease control OngoingThis study follows 284 people with blocked leg arteries (peripheral arterial disease) who are treated with a paclitaxel-coated balloon. The balloon is inflated inside the artery to open it and release a drug that helps prevent it from narrowing again. Researchers are tracking saf…
Sponsor: OrbusNeich • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo shows promise for lung cancer brain metastases
Disease control OngoingThis phase II trial tested whether adding bevacizumab to osimertinib works better than osimertinib alone for patients with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. Only 5 patients were enrolled. The goal was to see if t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a softer chemo regimen spare older breast cancer patients?
Disease control OngoingThis pilot trial is testing whether a lower-toxicity chemotherapy combination can be a feasible option for adults aged 70 and older with HER2-negative breast cancer. The study aims to see how well older patients tolerate the treatment and whether they can complete the planned cou…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could vitamin d and iron tame OCD's impulse control?
Disease control ENROLLING_BY_INVITATIONThis trial explores whether adding vitamin D and iron supplements to usual OCD treatment can improve the ability to control impulses. It involves 60 people with OCD who will receive the supplements for 12 weeks. Researchers will use brain scans and behavioral tasks to see if thes…
Phase: NA • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a simpler tooth procedure spare kids from root canals?
Disease control TerminatedThis study compares two dental procedures for treating severe pulpitis (tooth nerve inflammation) in children's baby molars. One is a standard full root canal treatment (pulpectomy), and the other is a less invasive option that removes only part of the nerve (pulpotomy). The goal…
Phase: NA • Sponsor: Nebu Philip • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a virus injected into brain tumors fight recurrence?
Disease control OngoingThis trial tests whether an experimental virus called C134 is safe when injected directly into the brain tumor in people with recurrent malignant glioma, including glioblastoma. Participants receive two doses of the virus during surgery to remove the tumor. The study focuses on s…
Phase: PHASE1 • Sponsor: James Markert, MD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cocktail aims to deeply suppress bone marrow cancer
Disease control OngoingThis study tests a combination of four drugs—daratumumab, carfilzomib, lenalidomide, and dexamethasone—in 39 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to see how many patients achieve a complete or stringent complete response after initial treatmen…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug under observation for rare genetic disorder
Disease control ENROLLING_BY_INVITATIONThis study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers will track side effects and how the drug affects their health over time. The goal is to gather more safety information, not to test if the drug cures the condition.
Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a vaccine tame this rare brain disease?
Disease control ENROLLING_BY_INVITATIONThis study tests a vaccine called AADvac1 in 146 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and thinking. The vaccine aims to target a protein linked to the disease and slow its progression. Participants will receive injections o…
Phase: PHASE2 • Sponsor: Adam Boxer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new drug help people with aspirin allergy, asthma, and nasal polyps?
Disease control OngoingThis Phase 2 trial is testing dupilumab (Dupixent) in 17 people with aspirin-exacerbated respiratory disease (AERD), a condition that includes asthma, nasal polyps, and severe reactions to aspirin. The study aims to see if the drug can reduce markers of inflammation and improve s…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Triple-Drug attack shows promise against tough liver cancer
Disease control OngoingThis study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail aims to outsmart ALK lung cancer
Disease control OngoingThis study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hospital program aims to keep COPD patients out of trouble after Flare-Ups
Disease control OngoingThis study tests whether a structured care program (called a transition bundle) helps people with COPD recover better after a serious flare-up. The program includes guided steps and regular check-ins. About 1,368 patients across 36 hospitals will take part. The goal is to see if …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Precision proton beams take aim at High-Risk prostate tumors
Disease control OngoingThis study tests whether a higher dose of proton radiation, focused on tumors seen on MRI, can better control high-risk prostate cancer. About 100 participants will receive radiation over 8-9 weeks, plus hormone therapy for 18 months. The goal is to lower the chance of cancer ret…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
Disease control ENROLLING_BY_INVITATIONThis trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New daily shot could help kids with hemophilia avoid bleeds
Disease control OngoingThis study tests a daily injection called concizumab in children under 12 with hemophilia A or B, with or without inhibitors. The goal is to see if it safely prevents bleeding episodes. Participants receive daily shots under the skin for at least 2 years, and the study tracks how…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control OngoingThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Cash for calories: AI-Powered rewards aim to boost weight loss
Disease control OngoingThis study tests whether offering personalized financial incentives can help 80 adults with obesity stick to a weight-loss program. Participants attend virtual group classes, log their calories, and weigh themselves regularly. The goal is to see if tailored rewards improve diet t…
Phase: NA • Sponsor: University of Utah • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo targets tough lung cancer in early trial
Disease control OngoingThis early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. Abou…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
Disease control OngoingThis phase 3 trial is testing whether a new type of targeted radiation therapy, called 177Lu-PSMA-I&T, can slow the progression of metastatic castration-resistant prostate cancer better than standard hormone therapy. The study enrolls men with prostate cancer that has spread and …
Phase: PHASE3 • Sponsor: Curium US LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New granule drug could ease tumors in toddlers with NF1
Disease control OngoingThis study tests a granule (sprinkle) form of the drug selumetinib in children aged 1 to under 7 years who have neurofibromatosis type 1 (NF1) with painful, inoperable tumors. The goal is to find the right dose, check safety, and see if it shrinks tumors. About 36 children will t…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Bladder cancer duo: BCG plus immunotherapy drug shows promise in early trial
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug duo aims to shrink lung tumors in First-Line trial
Disease control TerminatedThis phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many pat…
Phase: PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Gel shield could spare prostate cancer patients from radiation damage
Disease control OngoingThis study tests a gel called SpaceIT that is placed between the prostate and rectum before radiation therapy for prostate cancer. The gel acts as a spacer to reduce radiation reaching the rectum, potentially lowering side effects. About 230 adults with low- to intermediate-risk …
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Immune cell therapy shows promise for Hard-to-Treat melanoma
Disease control OngoingThis study tests a treatment that uses a patient's own immune cells (T-cells) to fight advanced melanoma. Some participants also receive a dendritic cell vaccine to boost the immune response. The goal is to see if the T-cells last longer and work better against the cancer. The tr…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for kids with arthritis: drug trial shows promise
Disease control OngoingThis study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control ENROLLING_BY_INVITATIONThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase: PHASE2, PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for hemophilia patients with inhibitors: STSP-0601 enters phase 3 trial
Disease control OngoingThis Phase 3 trial is testing STSP-0601, an injectable drug, to control bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). The study will enroll 40 participants aged 12 to 70 and measure how well the drug s…
Phase: PHASE3 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
Disease control OngoingThis trial is testing whether giving an extra round of chemotherapy before the usual chemoradiotherapy can improve outcomes for people with a certain type of nasopharyngeal cancer. Participants will either receive standard chemoradiotherapy alone or induction chemotherapy (gemcit…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to tame rare bleeding disorder
Disease control OngoingThis study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. First, healthy volunteers will receive a single dose to check safety. Then, HHT patients will recei…
Phase: PHASE1, PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New triple therapy aims to shrink abdominal tumors in colorectal cancer
Disease control OngoingThis phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will e…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Genetically modified immune cells take on eight cancer types in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new pill shrink the spleen in myelofibrosis?
Disease control OngoingThis trial is testing an experimental drug called flonoltinib in people with intermediate to high-risk myelofibrosis, a type of bone marrow cancer that often causes an enlarged spleen. Participants will be randomly assigned to receive either a low or high dose of flonoltinib, or …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can an immune booster make hormone therapy work better against prostate cancer?
Disease control OngoingThis trial is testing whether adding an immunotherapy drug called ipilimumab to the standard hormone therapy of abiraterone plus prednisone can help men with advanced prostate cancer that has spread and no longer responds to hormone treatment. The study includes men aged 18 and o…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail shows promise for rare cancers
Disease control OngoingThis phase 2 trial is testing whether a combination of two drugs, talazoparib and temozolomide, can shrink tumors in people with rare cancers that have spread. The study includes 14 participants with advanced rare solid tumors, such as pheochromocytoma or paraganglioma, who have …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a High-Fiber diet shield the gut during breast cancer therapy?
Disease control TerminatedThis trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…
Phase: NA • Sponsor: Scripps Health • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Milk fats tested as natural cholesterol fix
Disease control OngoingThis study looks at whether a daily dose of milk polar lipids (a type of fat found in milk) can improve cholesterol levels, reduce inflammation, and support gut health in adults with high cholesterol and abdominal obesity. Researchers will measure changes in blood fats and other …
Phase: EARLY_PHASE1 • Sponsor: University of Connecticut • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eye injection aims to slow vision loss from Age-Related macular degeneration
Disease control OngoingThis study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…
Phase: PHASE4 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New timing of chemo drugs may boost pancreatic cancer response
Disease control OngoingThis study is testing whether changing the timing of two chemotherapy drugs, gemcitabine and nab-paclitaxel, can improve tumor shrinkage in people with pancreatic cancer that has spread to other organs. About 67 participants will receive the drugs on an optimized schedule. The go…
Phase: PHASE2 • Sponsor: Anne Noonan • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Game on: VA tests fun incentives to get veterans moving
Disease control OngoingThis study looks at whether game-like features and social rewards can help overweight veterans with high blood pressure become more physically active. About 725 veterans will take part in a 9-month program where they either compete or cooperate to increase their daily steps. The …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo attack: radiation plus surgery for stubborn tumors
Disease control OngoingThis early-phase study is testing whether giving a radioactive drug called Lutathera both before and after surgery is safe for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. The trial will enroll 10 adults whose tumors are considered remo…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells target brain tumors in new trial
Disease control OngoingThis early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a dual protein blocker shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called HM97662 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking two proteins, EZH1 and EZH2, which are thought to help tumors grow. The study aims t…
Phase: PHASE1 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
AI-Crafted supplement aims to restore testosterone naturally
Disease control ENROLLING_BY_INVITATIONThis trial tests whether a daily nutritional supplement, designed with artificial intelligence to target gut bacteria, can increase testosterone production in men aged 30-65 with functional secondary hypogonadism—a condition where the body doesn't make enough testosterone despite…
Phase: NA • Sponsor: Varol TUNALI • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New study tackles obesity in endometrial cancer survivors
Disease control OngoingThis study helps early-stage endometrial cancer survivors with obesity start a weight management program and possibly take weight loss medications. Researchers want to see if referring patients to a weight loss clinic helps them begin treatment. The goal is to improve long-term h…
Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cancer drug CHS-114 enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for PSP: experimental drug LM11A-31 enters key trial
Disease control ENROLLING_BY_INVITATIONThis Phase 2 trial tests whether the drug LM11A-31 can slow the progression of Progressive Supranuclear Palsy (PSP), a rare brain disorder that affects movement and balance. About 147 people with early-stage PSP will receive either the drug or a placebo twice daily for several mo…
Phase: PHASE2 • Sponsor: Adam Boxer • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cell therapy takes on recurrent ovarian cancer
Disease control OngoingThis study tests a new treatment called ADP-A2M4CD8, made from a patient's own immune cells, for ovarian cancer that has returned. It is given alone or with another drug (nivolumab) to see if it can shrink tumors. About 66 people with a specific genetic marker (HLA-A*02 and MAGE-…
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a simple mineral boost recovery after pediatric colon surgery?
Disease control ENROLLING_BY_INVITATIONThis trial tests whether giving zinc supplements before and after colonic surgery in children can help protect the gut lining and reduce inflammation. Children aged 1 month to 18 years undergoing colonic surgery with anastomosis will be randomly assigned to receive either routine…
Phase: NA • Sponsor: Alexandria University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Parents key to fighting obesity in childhood cancer survivors
Disease control OngoingThis study tests a program that teaches parents how to help their child, a childhood cancer survivor, eat healthy and exercise more. The goal is to prevent or reduce obesity, which is a major risk for heart disease in these children. About 520 families will take part in one of tw…
Phase: NA • Sponsor: University of South Florida • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a vitamin B3 pill protect the brain's blood vessels in Parkinson's?
Disease control ENROLLING_BY_INVITATIONThis trial investigates whether nicotinamide riboside (NR), a form of vitamin B3, can improve blood vessel health in the brain, memory, and physical function in people with Parkinson's disease. Participants are randomly assigned to take either NR or a placebo daily for 12 weeks. …
Phase: NA • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can less radiation be safer for throat cancer?
Disease control OngoingThis trial tests whether giving radiation to a smaller area of the neck can prevent throat cancer from returning while reducing side effects. People with p16-positive oropharynx cancer (a type linked to HPV) who are getting radiation therapy may be eligible. The goal is to see if…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo attack on prostate cancer shows promise in early trial
Disease control OngoingThis phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…
Phase: PHASE2 • Sponsor: Xiao X. Wei, MD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Disease control OngoingThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that has stopped responding to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Prostate cancer drug enzalutamide tested for Long-Term safety in ongoing study
Disease control OngoingThis study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare cervical cancer: drug trial targets tumor control
Disease control OngoingThis study tests a drug called AK104 (Cadonilimab) in 18 adults with a rare, aggressive cervical cancer that has returned or spread after standard chemotherapy. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants receive the drug al…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo aims to wipe out hidden cancer cells after chemo
Disease control OngoingThis study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Lifeline drug mitapivat keeps flowing for rare blood disorder patients
Disease control ENROLLING_BY_INVITATIONThis study offers continued access to the drug mitapivat for adults with pyruvate kinase deficiency who completed an earlier Agios-sponsored trial and cannot get the drug commercially. Only 6 participants are enrolled, and the main goal is to monitor side effects. The study does …
Phase: PHASE4 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare blood cancers? early trial begins
Disease control OngoingThis early-phase study tests a new drug called INCB160058 in adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to check the drug's safety and how the body processes it. About 186 participants will receive the drug to find the right dose and…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Adjustable lens study tracks Long-Term vision results
Disease control ENROLLING_BY_INVITATIONThis study follows about 500 people who already had cataract surgery with a special adjustable lens (RxSight LAL) or a standard lens. Researchers want to see how well the lens works over time, focusing on vision sharpness and correction of astigmatism. Participants just need to c…
Sponsor: RxSight, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Steam vs. pills: new study tests better fix for enlarged prostate in sexually active men
Disease control OngoingThis study compares a minimally invasive water vapor treatment (REZŪM) to taking two drugs together for men with an enlarged prostate that didn't get better with one drug. It includes 155 sexually active men aged 45 and older. The goal is to see which approach better improves uri…
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental combo aims to tame aggressive lymphoma without chemo
Disease control OngoingThis early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could removing a catheter sooner after kidney transplant cut infection risk?
Disease control OngoingThis trial compares removing a urinary catheter on day 3 versus day 6 after a living donor kidney transplant. The goal is to see if earlier removal reduces urinary tract infections within 30 days without causing more complications like urine leaks. The study involves 172 adult ki…
Phase: NA • Sponsor: Fahim Kanani • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a single Immune-Targeting drug quiet an autoimmune kidney disease?
Disease control OngoingThis trial tests whether rituximab, an infusion drug that calms certain immune cells, can help people with idiopathic membranous nephropathy and nephrotic syndrome. Participants receive either rituximab or a placebo, and the study tracks how many achieve a significant reduction i…
Phase: PHASE3 • Sponsor: Shoichi Maruyama MD PhD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cream could zap precancerous skin spots
Disease control OngoingThis early-stage study tests a new cream called RLS-1496 for actinic keratosis, rough patches that can turn into skin cancer. About 24 adults will apply the cream to one forearm daily for 28 days, leaving the other arm untreated for comparison. Researchers will check if the cream…
Phase: PHASE1, PHASE2 • Sponsor: Rubedo Life Sciences, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding a targeted antibody to radiation keep lymphoma away?
Disease control OngoingThis study looks at whether adding the drug rituximab to standard radiation therapy helps people with early-stage follicular lymphoma stay cancer-free longer. About 81 patients with stage I or II low-grade lymphoma are being randomly assigned to get radiation alone or radiation p…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo therapy shows promise in kidney cancer fight
Disease control OngoingThis study tested two immunotherapy drugs, nivolumab and ipilimumab, in 85 adults with advanced kidney cancer that could not be removed by surgery. The goal was to see if stopping nivolumab early in those who responded well, or adding ipilimumab in those who did not, could better…
Phase: PHASE2 • Sponsor: Toni Choueiri, MD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Real-World check: do popular kidney stone & BPH devices hold up?
Disease control OngoingThis study is tracking 238 adults who are already scheduled to have a procedure for kidney stones or an enlarged prostate (BPH) using Boston Scientific devices. The main goal is to see how often serious side effects happen with these tools in real-world use. Researchers will also…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a nutrient in eggs keep malnourished kids from getting worse?
Disease control OngoingThis study tests whether adding choline (a nutrient found in eggs and meat) to a standard food supplement helps children with moderate acute malnutrition avoid becoming severely malnourished. About 1,500 children aged 6 to 59 months in Malawi will receive either the standard supp…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-stage study tests a new oral drug, FX-909, alone or with another drug (pembrolizumab) in people with advanced solid tumors, including a type of bladder cancer. The main goals are to check safety and find the best dose. About 120 adults will take part, taking daily pill…
Phase: PHASE1 • Sponsor: Flare Therapeutics Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot aims to slash sky-high cholesterol in rare genetic disease
Disease control OngoingThis study tests a new medicine called zodasiran in people aged 12 and older who have a rare genetic condition that causes extremely high cholesterol (homozygous familial hypercholesterolemia). The goal is to see if the drug can safely lower bad cholesterol levels over 12 months.…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug LP352 aims to control seizures in severe epilepsy over the long term
Disease control ENROLLING_BY_INVITATIONThis phase 3 study is testing the long-term safety and effectiveness of LP352 (Bexicaserin) in 324 children and adults with developmental and epileptic encephalopathy (DEE), including Dravet and Lennox-Gastaut syndromes. Participants who completed earlier studies will receive LP3…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Gentler chemo combo shows promise for older leukemia patients
Disease control OngoingThis study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted pill plus chemo shrink lung tumors before surgery?
Disease control OngoingThis phase 2 trial is testing whether giving the targeted drug furmonertinib along with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II to IIIB). Participants take furmonertinib daily for 9 weeks plus th…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New scan could spot hidden prostate cancer
Diagnosis OngoingThis phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 18, 2026 04:00 UTC
-
A Super-Microscope could spot acid reflux in Kids—Without guesswork?
Diagnosis TerminatedThis study explores whether a very high-powered microscope can help diagnose acid reflux disease (GERD) in children by examining tiny gaps between cells in the esophagus. Researchers will compare biopsy samples from children with GERD, those with a related condition called eosino…
Sponsor: Baylor College of Medicine • Aim: Diagnosis
Last updated Aug 18, 2026 04:00 UTC
-
New PET tracer could spot hidden prostate cancer spread
Diagnosis OngoingThis study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 18, 2026 04:00 UTC
-
Can a new PET tracer outsmart head and neck cancer metastases?
Diagnosis TerminatedThis Phase II trial investigates whether an experimental imaging agent called 89Zr-panitumumab can better identify metastatic lesions in people with head and neck squamous cell carcinoma. Participants receive the agent intravenously and then undergo PET/CT imaging, which is compa…
Phase: PHASE2 • Sponsor: Andrei Iagaru • Aim: Diagnosis
Last updated Aug 18, 2026 04:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis ENROLLING_BY_INVITATIONThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New scan could help doctors spot hidden prostate cancer spread
Diagnosis OngoingThis study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…
Phase: PHASE3 • Sponsor: Curium US LLC • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New MRI dye could help detect pancreatic cancer early
Diagnosis TerminatedThis pilot study tests whether a special MRI dye called hyperpolarized 13-C-pyruvate can help doctors tell the difference between harmless and dangerous pancreatic cysts. About 20 adults with pancreatic cysts who are scheduled for surgery will receive the dye and have an MRI scan…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Sound waves could make brain tumor diagnosis safer and smarter
Diagnosis OngoingThis trial explores whether focused ultrasound can enhance the release of tumor DNA into the blood and spinal fluid, potentially making liquid biopsies a more reliable way to diagnose brain tumors. Researchers will use MRI-guided focused ultrasound to partially ablate the tumor i…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
Diagnosis OngoingThis study tests whether two imaging tools—laser speckle contrast imaging (LSCI) and digital thermography—can objectively grade mesenteric traction syndrome (MTS), a frequent complication during abdominal surgery that causes low blood pressure, rapid heart rate, and facial flushi…
Sponsor: Rigshospitalet, Denmark • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Blood test may predict rapid kidney decline in diabetes
Diagnosis OngoingThis trial tests whether a blood-based test called KidneyIntelX can help doctors better manage type 2 diabetes patients with early to moderate chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this …
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
New mammogram technique could reduce unnecessary breast biopsies
Diagnosis OngoingThis study looks at whether a special type of mammogram called contrast-enhanced mammography (CEM) can more accurately predict breast cancer in women with suspicious calcium spots in the breast. About 59 women with large areas of these spots will get both a standard mammogram and…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden immune clues in tumors?
Diagnosis TerminatedThis phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New imaging agent could spot recurrent brain metastases more accurately
Diagnosis OngoingThis study tests a new imaging agent called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and suspected recurrent brain tumors will receive o…
Phase: PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can 3D imaging sharpen the diagnosis and surgery of a common hearing condition?
Diagnosis OngoingThis study investigates whether cone-beam computed tomography (CBCT), a 3D imaging technique, can improve the diagnosis and surgical treatment of otosclerosis, a condition where abnormal bone growth in the middle ear causes hearing loss. Researchers will enroll 100 adults suspect…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New PET tracer may spot lung cancer tumors
Diagnosis TerminatedThis early-stage study is testing a radioactive imaging agent called [18F]-C-SNAT4 to see how it travels through the body and whether it can help detect lung cancer on PET scans. About 20 healthy volunteers and people with lung cancer will receive the tracer and undergo scans. Th…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New imaging technique targets Hard-to-Find cancers
Diagnosis TerminatedThis study aimed to test a new two-step PET imaging method to better detect cancers that produce a substance called CA19-9, such as pancreatic, bladder, and gastrointestinal tumors. The plan was to give patients an antibody followed by a radioactive tracer to highlight cancer cel…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Swallow a string to test for stomach bug?
Diagnosis OngoingThis study tests a new device called the esophageal string test (EST) to diagnose H. pylori, a stomach bacteria that can cause ulcers and cancer. Participants swallow a capsule with a string inside that collects stomach fluids. Researchers compare the results to standard tests. T…
Phase: NA • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Malaria vaccine trial for pregnant women launches in mali
Prevention TerminatedThis Phase 1 trial in Mali will test the safety of the PfSPZ malaria vaccine in 400 healthy pregnant women aged 18-34. Participants will receive three injections of either the vaccine or a placebo. The study will monitor both mothers and their infants for up to a year after birth…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Aug 18, 2026 04:00 UTC
-
New probe aims to stop post-polypectomy bleeding in high-risk patients
Prevention OngoingThis study tests a special probe that checks blood flow in ulcers left after colon polyp removal. The goal is to see if using this probe to guide treatment can prevent delayed bleeding, especially in patients taking blood thinners or with large polyps. About 180 high-risk adults …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Aug 18, 2026 04:00 UTC
-
Twice-Yearly HIV prevention shot shows promise in women
Prevention OngoingThis study tests a new long-acting injection called lenacapavir, given every 6 months, to prevent HIV in cisgender women in the US. About 253 women will receive either the injection or daily pills (Truvada) to compare how well the drug works in the body, its safety, and how accep…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Aug 18, 2026 04:00 UTC
-
Can rewards and support keep drug users HIV-Free?
Prevention OngoingThis study tests a 24-week program called CoMPASS that uses rewards (contingency management) and extra support to help people who inject drugs take PrEP consistently for HIV prevention. About 526 participants with opioid use disorder will be enrolled. Those who don't stick with P…
Phase: NA • Sponsor: Yale University • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Can a common drug shield children with sickle cell from stroke?
Prevention OngoingThis trial asks whether hydroxyurea, a daily oral medication, can reduce the risk of a first stroke in children with sickle cell anemia. Researchers will use transcranial Doppler (TCD) ultrasound to measure blood flow in the brain, a key indicator of stroke risk, in children aged…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Could a vaccine stop cancer before it starts in BRCA carriers?
Prevention OngoingThis early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Can virtual doula sessions and home monitoring prevent preeclampsia in black women?
Prevention ENROLLING_BY_INVITATIONThis study will test a telehealth group prenatal care program called Centering HER in 72 low-income, predominantly Black pregnant women in Kansas who are at moderate or high risk for preeclampsia. Participants will receive routine care plus seven doula-led virtual group sessions,…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Facebook group aims to cut cancer risk in rural young adults
Prevention OngoingThis completed trial tested a 12-month social media program to help rural young adults (ages 18-26) adopt healthier habits and reduce cancer risk. Nearly 1,800 participants from four states joined a private Facebook group with daily posts on exercise, diet, nicotine, alcohol, sun…
Phase: NA • Sponsor: Klein Buendel, Inc. • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Twice-Yearly shot could revolutionize HIV prevention for drug users
Prevention OngoingThis study looks at a new way to prevent HIV in people who inject drugs. It tests a shot given under the skin every 6 months (lenacapavir) and compares it to daily pills. The goal is to see how well the shot works in the body and if it is safe. About 181 people in the US are taki…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Can a pair of glasses slash motorcycle crashes?
Prevention OngoingThis trial tests whether providing free corrective glasses to young motorcycle drivers with myopia (nearsightedness) can reduce the number of crashes and near-misses. Participants are university students in Ho Chi Minh City who drive regularly and have uncorrected or under-correc…
Phase: NA • Sponsor: Queen's University, Belfast • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
Prevention OngoingThis trial tests two strategies for preventing cervical cancer in women living with HIV in Tanzania. Both strategies involve HPV self-sampling and visual checks of the cervix, but they differ in the timing of HPV vaccination. The study aims to see which approach better reduces pr…
Phase: NA • Sponsor: Queen's University • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Step up against dementia: fitbit app aims to boost walking in middle age
Prevention ENROLLING_BY_INVITATIONThis study tests whether a smartphone app that sets daily step goals can help middle-aged adults (30-70 years old) who are overweight walk more. Participants use a Fitbit and receive adaptive goals to increase light physical activity. The goal is to see if this simple approach ca…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Hidden fat in slim women: could exercise and diet cut breast cancer risk?
Prevention OngoingThis study tests whether a lifestyle program combining aerobic exercise, strength training, and dietary coaching can reduce breast cancer risk in normal-weight postmenopausal women. The goal is to lower body fat and inflammation, which are linked to higher cancer risk even in wom…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Could a smartphone app curb childhood obesity? a new study tests two rollout strategies
Prevention OngoingThis study looks at how to best bring MINISTOP 3.0, a mobile app for parents, into Swedish primary child healthcare. The app aims to help parents of 2.5- to 3-year-olds encourage healthy eating, physical activity, and less screen time. Researchers will compare two ways of rolling…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Antibiotic wash for breast implants could cut surgery failures
Prevention OngoingThis study tests whether rinsing breast implants with a mix of three antibiotics before placing them can reduce the chance of the implant being removed later. About 1,000 women having breast reconstruction after cancer will be randomly assigned to get the antibiotic rinse or a pl…
Phase: PHASE3 • Sponsor: Mikkel Herly • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
A smarter way to hand out overdose reversal kits?
Prevention OngoingThis trial tests a strategy called SAIA-N, which uses coaching and data review to help syringe service programs in California distribute more naloxone, a medication that reverses opioid overdoses. About 31 programs will either use this strategy for a year or continue their usual …
Phase: NA • Sponsor: RTI International • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a smallpox vaccine stop mpox in its tracks?
Prevention OngoingThis trial tests whether giving the smallpox vaccine to people who have been exposed to mpox can prevent them from getting sick or reduce the severity of the disease. It involves about 3,000 household members of people with confirmed mpox, who receive either the vaccine or a cont…
Phase: PHASE4 • Sponsor: McMaster University • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a nerve stimulator turn down the fire of erythromelalgia?
Symptom relief OngoingThis trial tests whether spinal cord stimulation can reduce severe, treatment-resistant pain in people with erythromelalgia, a rare condition causing red, hot, and painful extremities. Participants receive either burst stimulation or sham (inactive) stimulation to see if the ther…
Phase: NA • Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Can a Two-Drug combo beat single painkiller after stomach surgery?
Symptom relief OngoingThis trial tests whether a combination of acetaminophen and ibuprofen (Maxigesic) given through an IV can control pain better than acetaminophen alone after laparoscopic or robotic stomach cancer surgery. About 90 adults undergoing this surgery will be randomly assigned to one of…
Phase: PHASE2 • Sponsor: Seoul National University Bundang Hospital • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Shorter radiation course may spare breast cancer patients side effects
Symptom relief OngoingThis study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is t…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Can group family therapy help teens beat anorexia?
Symptom relief OngoingThis study tests a multi-family therapy program for teens aged 11–18 with anorexia nervosa and their families. The therapy brings several families together to share support and learn skills for meal support and emotional regulation. Researchers will track weight, eating disorder …
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
New app aims to ease cancer symptoms for rural patients
Symptom relief TerminatedThis study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
New obesity drug enters early human testing
Symptom relief OngoingThis early-stage study tests a new medicine for people who are overweight or have obesity. The main goal is to check if the medicine is safe and how the body processes it. About 63 participants will receive either the study drug or a placebo as an injection under the skin. The me…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Cream showdown: aquaphor vs miaderm for radiation burns
Symptom relief OngoingThis study compares two creams, Aquaphor and Miaderm, to see which one better treats skin irritation caused by radiation therapy in breast cancer patients. About 208 women with early-stage breast cancer will use one of the creams during their radiation treatment. The goal is to f…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Video analysis could personalize rehab for chemo nerve damage
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…
Phase: NA • Sponsor: Seoul National University Bundang Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Ear seeds may boost IVF success by calming anxiety
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a simple ear acupressure technique, called auricular point sticking therapy, can reduce anxiety and improve sleep in women undergoing IVF. 178 women aged 20-45 with anxiety or insomnia will either receive standard IVF care or standard care plus ear acupre…
Phase: NA • Sponsor: Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can a video weight loss program help breast cancer survivors?
Symptom relief OngoingThis study tested a 24-week weight loss program delivered via video calls for 22 breast cancer survivors who were overweight or obese. The goal was to see if the program was practical and well-liked, and whether it improved quality of life, physical activity, and mood. Participan…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New study tests workplace coaching to keep Parkinson's patients on the job
Symptom relief OngoingThis study tests a personalized workplace intervention for 124 Dutch workers with Parkinson's disease, cerebellar ataxia, hereditary spastic paraparesis, or slowly progressive neuromuscular/mitochondrial disorders. A trained facilitator helps employees and their managers identify…
Phase: NA • Sponsor: Radboud University Medical Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Walking through chemo: new study tests exercise for older breast cancer patients
Symptom relief OngoingThis study looks at whether a regular exercise program is practical for women aged 65 and older who are receiving chemotherapy for early-stage breast cancer. Participants will be asked to walk and do arm exercises several times a week. The goal is to see if exercise can reduce th…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Nature as therapy? a new trial tests outdoor outings for anxious kids
Symptom relief TerminatedThis trial tests whether spending time in nature can reduce anxiety in children aged 9-12 who have experienced adverse childhood events. Participants are assigned to either group nature outings, family outings, or a waitlist. The goal is to see if these nature-based activities im…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Iron shot boosts heart Patients' stamina, study hopes
Symptom relief OngoingThis study tests whether a single dose of intravenous iron (ferric derisomaltose) can improve exercise capacity in people with heart failure with preserved ejection fraction who also have iron deficiency. About 66 adults will receive either the iron infusion or a placebo, and the…
Phase: PHASE4 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can early sexual health counseling transform breast cancer recovery?
Symptom relief OngoingThis trial asks whether starting sexual health support early and systematically helps women with localized breast cancer feel better about their sexual well-being compared to waiting until they ask for help. Women aged 18 and older who are beginning treatment with surgery will re…
Phase: NA • Sponsor: Center Eugene Marquis • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Intermittent fasting tested to ease radiation side effects in cancer patients
Symptom relief OngoingThis phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Pen and paper: a new weapon against blood cancer stress?
Symptom relief OngoingThis study explores whether an online expressive writing workshop can boost mental wellness in young adults (ages 18-39) with blood cancer. One hundred participants will either start the workshop right away or wait four weeks. Everyone takes surveys about their mood and stress ov…
Phase: NA • Sponsor: Blood Cancer United • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Rubber band trick may take the sting out of IV needles
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether using a hand extension rubber during IV insertion can reduce pain, anxiety, and improve satisfaction. Researchers will enroll 114 adults who need an IV and randomly assign them to use the rubber or not. The goal is to see if this simple, low-cost distract…
Phase: NA • Sponsor: Necmettin Erbakan University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can a smartphone app help young cancer survivors get moving and improve their quality of life?
Symptom relief OngoingThis study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
AI reads your social media to boost breast cancer mental health
Symptom relief OngoingThis study tests whether an AI system that analyzes social media posts can improve quality of life for breast cancer patients. 440 women will either use the AI system plus usual care or just usual care for 6 months. The goal is to see if personalized emotional support reduces anx…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Faith-Based therapy aims to heal trauma in young women
Symptom relief OngoingThis trial tests a counseling program called Mpata Yathu ('Our Space') for adolescent girls and young women in Zambia who have experienced gender-based violence and may be living with or at risk for HIV. The program uses problem-solving therapy delivered by trained lay counselors…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New gel shields bowel during prostate radiation – could cut side effects
Symptom relief OngoingThis trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Acupuncture needles aim to zap cancer brain fog
Symptom relief OngoingThis phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Healing from home: virtual reiki tested for lupus pain relief
Symptom relief OngoingThis pilot study will test whether virtual Reiki therapy can reduce pain and improve well-being in people with lupus. Twenty adults with lupus will receive 20-minute Reiki sessions once a week for 8 weeks, delivered remotely by a certified practitioner. Researchers will measure c…
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a smartphone app boost exercise and ease symptoms in breast cancer survivors?
Symptom relief OngoingThis study looks at whether a mobile health program that combines physical activity tracking with mindfulness lessons can help breast cancer survivors become more active and feel better. About 304 women who finished cancer treatment within the past 5 years will take part in a 24-…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Exercise program shows promise for lingering COVID symptoms
Symptom relief OngoingThis study tests whether a 10-week aerobic exercise program can improve physical function and reduce symptoms in adults still struggling after a COVID-19 infection. Participants will exercise three times a week and attend weekly education classes. The goal is to see if exercise h…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Couples tackle brain tumors together with online Mind-Body program
Symptom relief OngoingThis study tests an online mind-body program designed for people with brain tumors (glioma) and their partners. The program aims to improve spiritual well-being, sleep, mood, and overall quality of life for both. Researchers are enrolling 74 couples to see if the program is pract…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Video workouts before pancreatic surgery: a new hope?
Symptom relief OngoingThis study tests whether a supervised, video-based exercise program done at home during chemotherapy can help people with pancreatic cancer get stronger before surgery. About 58 patients will take part. The goal is to see if the program is safe and helps improve recovery.
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
NIH launches biobank to unlock DNA secrets of Women's cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists hunt for diabetes genes in large study
Knowledge-focused TerminatedThis study looks at the genetic and molecular factors behind type 2 diabetes, obesity, and related complications like kidney disease. Researchers will collect health information, blood and urine samples, and perform tests like eye exams and ultrasounds from over 2,300 adults, foc…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
App aims to boost nutrition for GLP-1 users
Knowledge-focused OngoingThis study tests a smartphone app designed to help adults taking GLP-1 medications for obesity or type 2 diabetes eat better. About 50 participants will use the app for 6 weeks to track their diet and learn about nutrition. The goal is to see if the app is helpful and easy to use…
Phase: NA • Sponsor: University of South Carolina • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Do extra biopsies during colonoscopy help IBD patients? major study aims to find out
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether taking extra random biopsies during a colonoscopy helps find precancerous growths in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 1,600 participants will be randomly assigned to one of two biopsy…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists dig into tissue samples to unravel lung scarring mystery
Knowledge-focused OngoingThis study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
New drug zavicefta under Real-World watch for sepsis and kidney patients
Knowledge-focused OngoingThis study will observe how safe and effective the antibiotic Zavicefta is when used in everyday medical practice in Japan. It includes 59 patients with sepsis (a severe blood infection) or reduced kidney function who are receiving Zavicefta for the first time. Researchers will t…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Childhood farm life under the microscope: could pesticides raise cancer risk?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists watch brain tumors transform using advanced imaging
Knowledge-focused TerminatedThis study tracks a substance called 2-HG in the brains of people with a type of brain cancer (glioma) that has specific gene changes. By using special MRI scans over time, researchers hope to learn how and when these tumors become more aggressive. About 42 adults will have regul…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Blood test may help cancer patients stop treatment early
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tumor DNA can help doctors decide when to safely stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show no signs of …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Brain scans reveal secrets of lost smell
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks 80 adults with different smell disorders (like total loss, partial loss, or distorted smell) plus healthy volunteers over one year. Researchers use brain scans, smell tests, and questionnaires to see how the brain changes and how smell loss impacts mood and dail…
Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
New imaging technique could reveal brain tumor metabolism
Knowledge-focused OngoingThis study tests a new way to measure brain metabolism using a special glucose drink and MRI scans. Researchers will compare healthy volunteers and people with glioma (a type of brain tumor) to see if the technique can detect differences in energy use. The goal is to improve imag…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
NIH opens screening study to find candidates for blood disorder research
Knowledge-focused ENROLLING_BY_INVITATIONThis study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Can a dengue vaccine be both Cost-Effective and trusted? a thai study investigates
Knowledge-focused OngoingThis study has two parts. First, researchers will use computer models to estimate whether giving the TAK-003 dengue vaccine to Thai children aged 9-14 or young adults aged 15-24 would be good value for money for the national immunization program. Second, they will survey Thai adu…
Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists collect skin cells to pave way for future immune disease cures
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Researchers collect blood to solve mystery of drug side effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood samples from people already in other NIH clinical trials who are having or are expected to have serious side effects from their drugs. The goal is to measure drug levels in the blood to better understand why side effects happen. Up to 100 participants ag…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Cancer drug interaction study: will antibiotics change how cediranib works?
Knowledge-focused OngoingThis Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Gene therapy patients monitored for 15 years to spot hidden side effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists track rare eye disease to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 46 people with gyrate atrophy, a rare genetic condition that causes vision loss, over 4 years. Researchers measure ornithine levels in the blood and track changes in the retina using eye scans and photos. The goal is to learn how the disease progresses under st…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Counting the uncounted: a nationwide look at two rare epilepsies
Knowledge-focused TerminatedThis observational study aims to measure how many people in Portugal have Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), two rare and severe forms of epilepsy. Researchers will review existing medical records from about three public hospitals to estimate the percentage of…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Massive cancer screening trial aims to cut deaths
Knowledge-focused OngoingThis study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Penile cancer patients share surgery experiences to improve future care
Knowledge-focused TerminatedThis study surveys 20 penile cancer patients who have had groin lymph node surgery at least 6 months ago. Researchers use questionnaires to learn about patients' experiences, needs, and symptoms. The goal is to find ways to improve care and education for future patients.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New study aims to pinpoint fastest Crohn's symptom relief
Knowledge-focused OngoingThis study follows 300 adults with Crohn's disease who are starting standard treatments like vedolizumab or IL-23 blockers. Researchers will track how quickly patients feel improvements in pain, fatigue, and daily functioning using simple questionnaires. The goal is to better und…
Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Why are transplant survivors at higher heart risk? new study seeks answers
Knowledge-focused OngoingThis study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Smartwatch could spot nerve damage before it starts
Knowledge-focused TerminatedThis study follows women with early-stage breast cancer who are about to receive paclitaxel chemotherapy, a treatment that often causes nerve damage. Researchers will use smartwatches and a mobile app to track physical activity, sleep, and stress, alongside clinical exams and ski…
Sponsor: Theodoros Foukakis • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Fiber-Fueled immunity: could your diet boost the flu shot?
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet (rich in fruits, vegetables, and whole grains) can change the bacteria in your gut and improve how well the flu vaccine works. Researchers will give 31 adults special meals and snacks before they get their flu shot. The main go…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Could muscle loss predict blood cancer outcomes?
Knowledge-focused OngoingThis study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Digital tools aim to close learning gaps for young cancer survivors
Knowledge-focused OngoingThis study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a 7-Day genomic test improve lymphoma treatment?
Knowledge-focused OngoingThis study looks at whether a new genomic test called the Molecular Functional (MF) Portrait can quickly provide useful information for treating lymphoma. Researchers will use tumor tissue already collected from 111 adults with diffuse large B-cell lymphoma to see if test results…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Video lessons may boost cancer gene knowledge
Knowledge-focused OngoingThis study looks at whether short educational videos can help people with inherited cancer gene mutations learn more about their condition. About 43 adults who carry mutations in genes like BRCA1 or BRCA2 will watch the videos and then take a quiz. The goal is to see if this simp…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Hidden heart risks in Wilson's disease: a new scan could spot them early
Knowledge-focused OngoingThis study investigates whether children with Wilson's disease, who appear to have normal heart function, may actually have subtle heart problems. Using advanced echocardiography, ECG, and a blood test for a heart stress marker, researchers will compare these children to healthy …
Sponsor: Hebatullah Fawzy • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Massive Alzheimer's study aims to unlock secrets of memory loss
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1,500 volunteers with normal memory, mild cognitive impairment, or Alzheimer's over several years. Researchers use brain scans, memory tests, and blood samples to track how the disease progresses. The goal is to find better ways to diagnose and treat Alzheimer'…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can cancer patients get better care at home? MD anderson investigates
Knowledge-focused TerminatedThis study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Could your bone health decide if a dental implant lasts?
Knowledge-focused OngoingThis study looks back at dental implant cases to see if bone-related conditions—like vitamin D deficiency, calcium problems, or kidney disease—make implant failure more likely. Researchers will compare 192 failed implants with successful ones from similar patients. The goal is to…
Sponsor: University of Barcelona • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can smarter antibiotic use curb Drug-Resistant infections?
Knowledge-focused OngoingThis study looks back at medical records from four hospitals in Thailand to understand what happens when doctors reduce antibiotic treatment (de-escalation) in patients who received short-course IV antibiotics. It compares outcomes like new resistant infections and death between …
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can lifestyle choices after a stroke extend life and prevent a second one?
Knowledge-focused OngoingThis study follows 800 adults who have had their first ischemic stroke in Central Norway for up to 10 years. Researchers will track how physical activity, medication use, and control of blood pressure and cholesterol affect the risk of death, another stroke, or severe disability.…
Sponsor: Norwegian University of Science and Technology • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a machine learning model beat standard tools in spotting sepsis early?
Knowledge-focused OngoingThis study compares a standard early-warning system called NEWS2 with a machine-learning model to see which can detect sepsis earlier in hospital patients. Researchers will monitor 100 adults admitted with suspected infection, recording when each system first raises an alert and …
Sponsor: Kocaeli Derince Education and Research Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New study tracks rare disease SCA7 to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
COVID-19 survivors tracked for 3 years to uncover hidden health impacts
Knowledge-focused OngoingThis study follows 583 adults who recovered from COVID-19 or were close contacts. Researchers will track their health, mental well-being, and immune responses over 3 years to understand long-term effects and whether prior infection prevents reinfection. Participants undergo regul…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Rare bone cancer study hunts for hidden genetic triggers
Knowledge-focused OngoingThis study aims to find genetic changes that may cause sporadic chordoma, a rare bone cancer. Researchers will collect saliva and medical records from 188 patients across the U.S. and Canada who are the only ones in their family with chordoma. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind family blood cancer clusters
Knowledge-focused OngoingThis long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Blood test may help cancer patients avoid nerve damage from chemo
Knowledge-focused TerminatedThis pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
What raises endometrial cancer risk in black women? a study digs in
Knowledge-focused OngoingThis study looks at risk factors for endometrial cancer in Black women, a group that may face different risks. Researchers will compare women recently diagnosed with the cancer to healthy volunteers, using questionnaires and interviews. The goal is to understand what factors matt…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can we finally outsmart recurrent yeast infections? a new study investigates
Knowledge-focused OngoingThis study aims to understand why some women get recurrent vaginal yeast infections (vulvovaginal candidiasis) and others don't. Researchers will compare the vaginal microbiome, immune markers, and metabolic profiles of women with and without the infection. By identifying key dif…
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
AI and quick looks: could they speed up breast cancer screening?
Knowledge-focused OngoingThis study tested whether radiologists can safely skip looking at detailed 3D breast scans when a quick 2D image or an AI score suggests the case is normal. Sixteen radiologists briefly viewed each case and rated how likely it was normal, then saw the AI's opinion. The goal is to…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Tiny study probes Mitapivat's inner workings in sickle cell
Knowledge-focused OngoingThis observational study will examine how the drug mitapivat changes red blood cells in 6 people with sickle cell disease. Researchers will measure oxygen binding and cell survival markers from blood samples and muscle oxygen tests. The goal is to understand the drug's effects, n…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive study aims to uncover hidden triggers of blood cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study is collecting blood, bone marrow, and tissue samples from 5,000 people with blood cancers like leukemia and lymphoma. Researchers will analyze the samples to find genetic abnormalities that cause cancer cells to grow. The goal is to understand why these cancers develop…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can stress sabotage your diet? new study investigates
Knowledge-focused OngoingThis study follows 50 adults in a community weight loss program to see how daily stress levels relate to weight loss, physical activity, and sleep. Participants will answer quick surveys on their phones and wear a wrist device to track activity and sleep. The goal is to understan…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Blood samples sought to unlock secrets of sickle cell disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood and other samples from people with sickle cell disease and healthy volunteers to help researchers understand how inflammation affects blood vessels. Up to 2,000 adults aged 18 and older will take part. The samples will be used in lab tests to support fut…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Cured of hepatitis c? this study follows patients for 10 years to see what happens next
Knowledge-focused OngoingThis study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …
Phase: PHASE4 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Cell collection study paves way for future cancer therapies
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
PET scans may predict breast cancer drug response before surgery
Knowledge-focused OngoingThis study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New screening study targets hidden diabetes and celiac disease in High-Risk communities
Knowledge-focused OngoingThis study is screening 115 underserved children and adults who are at risk for type 1 diabetes or celiac disease. Researchers will use blood tests to find early signs of these conditions, aiming to improve how we detect them. The goal is to catch these diseases sooner, especiall…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hunt for prostate cancer genes in 24,000 men
Knowledge-focused OngoingThis study looks for genetic changes that raise the risk of prostate cancer, especially in men diagnosed young or with a family history. Over 23,800 men with prostate cancer provided DNA samples. The goal is to find inherited genes linked to the disease, which could improve risk …
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
CT scans may predict breast reconstruction flap failure
Knowledge-focused OngoingThis study looks at whether a new scoring system, called the DIEP-MDS, can help predict the risk of blood flow problems and flap failure after DIEP flap breast reconstruction. The score is based on CT scans of the abdomen, measuring features of the blood vessels used in the surge…
Sponsor: Zhuliling • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Could a ketone drink help fight colorectal cancer? a trial investigates
Knowledge-focused OngoingThis study is testing whether a ketone supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people scheduled for a colonoscopy or flexible sigmoidoscopy as part of their standard care. Participants will take a drink containing R-1,3-butanediol three times daily …
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can MRI scans reveal how ANO5 muscle disease progresses?
Knowledge-focused OngoingThis study follows adults with pathogenic variants in the anoctamin 5 gene, which causes a form of limb-girdle muscular dystrophy. Over three years, researchers will use whole-body MRI to measure changes in muscle fat content, and questionnaires to track fatigue and quality of li…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Blood marker may predict nerve damage onset in rare genetic disease
Knowledge-focused OngoingThis observational study is looking at a protein called neurofilament light chain (NfL) in the blood of people who carry a gene variant for hereditary ATTR amyloidosis, both those without symptoms and those with nerve damage. Researchers want to see if NfL levels can help detect …
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Scientists dive deep into RSV vaccine immune secrets
Knowledge-focused OngoingThis study looks at how the RSV vaccine affects the immune system in adults aged 60 and older. Researchers will take blood samples before and after vaccination to find early signs of protection. The goal is to understand why some people respond better than others. 14 volunteers w…
Phase: PHASE4 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can Lab-Grown placenta tissue reveal how zika and tonate viruses strike?
Knowledge-focused TerminatedThis study investigates whether Zika and Tonate viruses can replicate in human placental tissue grown in the lab. Researchers will infect placental samples from early and full-term pregnancies and measure viral levels to compare how each virus behaves. The goal is to better under…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can MRI scans reveal the hidden pattern of muscle damage in a rare muscular dystrophy?
Knowledge-focused OngoingThis study aims to describe the pattern of muscle involvement in people with limb girdle muscular dystrophy caused by mutations in the anoctamin 5 gene. Researchers will collect and analyze MRI scans from 200 participants to see which muscles are affected and how much fat replace…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
HIV and hidden health risks: a major study probes the link
Knowledge-focused OngoingThis study compares over 1,500 people living with HIV to a similar group from the general population to see if conditions like heart disease, COPD, and liver disease are more common or develop faster in those with HIV. Using detailed scans and tests, researchers will measure the …
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Simple blood test may predict lymphoma treatment success
Knowledge-focused OngoingThis study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New simulation curriculum aims to ease the aches of OR workers
Knowledge-focused OngoingThis study aims to create a hands-on training program to teach operating room teams—surgeons, anesthesiologists, and nurses—how to work more comfortably and avoid injuries. Poor ergonomics causes pain in over half of OR staff, leading to burnout and early retirement. The project …
Sponsor: Sunnybrook Health Sciences Centre • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New tool lets young cancer patients speak up about symptoms
Knowledge-focused OngoingThis study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a vaccine shield transplant patients from shingles?
Knowledge-focused OngoingThis study looks at how the immune system of kidney transplant patients responds to the shingles vaccine and to natural shingles infection. Researchers will track antibody and T-cell levels over time in patients who have had a transplant or are on the waiting list. The goal is to…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Are clinics missing advanced HIV cases? a new study investigates
Knowledge-focused TerminatedThis study looks at how often CD4 cell counts are measured when adults in Zambia begin or restart antiretroviral therapy (ART) after a long break. The goal is to see how many people have advanced HIV disease and whether low testing rates prevent proper care. Researchers will asse…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immune cells predict herpesvirus danger in transplant patients?
Knowledge-focused OngoingThis study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ re…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused TerminatedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Gut bugs may boost flu vaccine power
Knowledge-focused OngoingThis study looks at whether the bacteria in your gut and what you eat can influence how well the flu vaccine works. Researchers will collect blood and stool samples from 74 adults before and after they get their flu shot. The goal is to find links between gut microbiome diversity…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC